The use of a VDR-ligand to reprogram the pancreatic cancer stroma was a major breakthrough for pancreatic cancer research and has since prompted Vitamin D analogs to be included in numerous ongoing clinical trials (Table 1). This evidence concerns the gene VDR and pancreatic neoplasm.